Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Gene Therapy for HIV-related Lymphoma
NCT02797470Phase 2Active, not recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- Jun 2016
- Primary completion
- May 2021
- Modality
- Gene Editing, Viral-delivered RNAi, Lentiviral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells in human immunodeficiency virus infection (HIV) and lymphoma, sponsored by AIDS Malignancy Consortium. Primary endpoint: Percentage of Participants Who Achieve a Timely Engraftment at 1 month. Started Jun 2016; status: active, not recruiting.
02
Drugs
lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
03
Conditions
human immunodeficiency virus infection (HIV)lymphoma
Beyond the preview
Go deeper on NCT02797470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797470.